Advertising
The TGA regulates advertisements for therapeutic goods. You need to know if that includes the product you intend to advertise.
Advertising non-compliance reports and investigation outcomes
Latest alerts
- EVE Allylisopropylacetylurea tabletsThe TGA is warning consumers against taking EVE branded products that contain allylisopropylacetylurea (apronal) as they pose a significant health risk and are prohibited from sale, supply or use in Australia.
- Counterfeit semaglutide vialsThe TGA has detected fake semaglutide, also known as Ozempic, being illegally imported into Australia.
Latest articles
- EmpireLabz Australia Pty Ltd fined $115,500 for alleged unlawful advertising and supply of sport supplementsThe TGA has issued 7 infringement notices totalling $115,500 to the company for the alleged unlawful advertising and supply of sport supplement products containing banned substances.
- Trava Health Pty Ltd fined for alleged unlawful advertising of medicinal cannabisThe TGA has issued five infringement notices totalling $82,500 were issued to the company, and 3 notices totalling $9,900 were issued to an individual.
- Vaping products, medicinal cannabis and the wellness industry included in 2023-24 compliance and enforcement prioritiesRead about our import, advertising and supply compliance priorities for 2023-24.
Latest publications
- Therapeutic goods advertising compliance: 2022-23 Annual ReportOverview of therapeutic goods advertising complaints handling and compliance for 2022-23
- Therapeutic Goods Advertising and Compliance Education Plan 2023This plan outlines the compliance and education priorities of the Therapeutic Goods Administration for 2023.
- Therapeutic Goods Advertising Consultative Committee, 2 December 2022Communique from the meeting of the TGACC